PL3973959T3 - Leczenie świądu cholestatycznego za pomocą seladelparu - Google Patents

Leczenie świądu cholestatycznego za pomocą seladelparu

Info

Publication number
PL3973959T3
PL3973959T3 PL21201888.1T PL21201888T PL3973959T3 PL 3973959 T3 PL3973959 T3 PL 3973959T3 PL 21201888 T PL21201888 T PL 21201888T PL 3973959 T3 PL3973959 T3 PL 3973959T3
Authority
PL
Poland
Prior art keywords
pruits
seladelpar
cholestatic
treatment
cholestatic pruits
Prior art date
Application number
PL21201888.1T
Other languages
English (en)
Polish (pl)
Inventor
Pol Boudes
Charles A. Mcwherter
Alexandra S. Steinberg
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of PL3973959T3 publication Critical patent/PL3973959T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL21201888.1T 2017-09-26 2018-09-24 Leczenie świądu cholestatycznego za pomocą seladelparu PL3973959T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
PL3973959T3 true PL3973959T3 (pl) 2025-03-24

Family

ID=64564950

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21201888.1T PL3973959T3 (pl) 2017-09-26 2018-09-24 Leczenie świądu cholestatycznego za pomocą seladelparu
PL18811954T PL3687523T3 (pl) 2017-09-26 2018-09-24 Leczenie świądu cholestatycznego za pomocą seladelparu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18811954T PL3687523T3 (pl) 2017-09-26 2018-09-24 Leczenie świądu cholestatycznego za pomocą seladelparu

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3687523B1 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE070033T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3973959T3 (enExample)
PT (2) PT3687523T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) * 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease
US20260207538A1 (en) 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ES2701094T3 (es) * 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3973959B1 (en) 2024-12-11
RU2020114644A (ru) 2021-10-27
US20190105291A1 (en) 2019-04-11
MX2020007273A (es) 2022-05-23
CA3076614C (en) 2023-02-07
IL288340B2 (en) 2023-05-01
WO2019067373A1 (en) 2019-04-04
SG11202002253SA (en) 2020-04-29
AU2021254641A1 (en) 2021-11-18
CY1124894T1 (el) 2023-01-05
ES2902349T3 (es) 2022-03-28
HUE070033T2 (hu) 2025-05-28
HRP20212010T1 (hr) 2022-04-01
LT3687523T (lt) 2022-03-25
EP4523744A3 (en) 2025-06-04
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
CN111132675A (zh) 2020-05-08
DK3973959T3 (da) 2025-01-20
LT3973959T (lt) 2025-01-10
AU2021254641B2 (en) 2022-02-24
FI3973959T3 (fi) 2025-02-03
IL273569A (en) 2020-05-31
EP3973959A1 (en) 2022-03-30
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
US20210283078A1 (en) 2021-09-16
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
HUE057377T2 (hu) 2022-05-28
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
ZA202001646B (en) 2021-08-25
SI3973959T1 (sl) 2025-03-31
AU2018342323B2 (en) 2021-09-23
KR20200058458A (ko) 2020-05-27
PT3973959T (pt) 2025-01-24
BR112020005074A2 (pt) 2020-09-15
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
EP3687523B1 (en) 2021-11-03
IL288340A (en) 2022-01-01
PT3687523T (pt) 2021-12-06
EP3687523A1 (en) 2020-08-05
ES3012120T3 (en) 2025-04-08
NZ762976A (en) 2021-11-26
IL273569B (en) 2021-12-01
CA3076614A1 (en) 2019-04-04
JP2020535225A (ja) 2020-12-03
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
JP7023371B2 (ja) 2022-02-21
CN111132675B (zh) 2023-04-25
RS62790B1 (sr) 2022-02-28

Similar Documents

Publication Publication Date Title
PL3687523T3 (pl) Leczenie świądu cholestatycznego za pomocą seladelparu
IL293377B1 (en) Hsd17b13 variants and uses thereof
IL282048A (en) Oxysterols and methods of use thereof
IL269371A (en) Treatment methods
DK3134530T3 (da) Behandling af hyperbilirubinæmi
IL263680A (en) Combination therapies
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP3420388A4 (en) PUPILS EQUALIZATION
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
IL272851A (en) Methods of using dipivefrin
SI3518783T1 (sl) Naprava za zmanjševanje tkiva
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PT3645518T (pt) Síntese de omecamtiv mecarbil
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3307267T3 (da) Behandling af multipel sklerose
DK3283210T3 (da) Fremgangsmåde
PL3393468T3 (pl) Metody leczenia niedoboru odporności
HRP20181914T1 (hr) Liječenje intrahepatičnih kolestatskih bolesti
LT3576740T (lt) Vėžio gydymas
HUE055778T2 (hu) Oligo-ovulációval összefüggõ májzsírosodás kezelése
IL254825A0 (en) Methods of treatment with taselisib
PL3661510T3 (pl) Sposoby leczenia zmian zachowania
DK3638370T3 (da) Behandling af migræne med acetyl-leucin
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme